Japanese dendritic cell cancer immunotherapy and stem cells
What are Japanese dendritic cell cancer immunotherapy and stem cells?
The immunotherapy we provide is "activated NK cell therapy" and "activated NK/NKT/NGT cell therapy" that use "multivalent dendritic cell vaccine" to gain immunity and then attack specific cancers and strengthen innate immunity. . The identification methods of various cancer cells are different. No matter which type of immunotherapy, it will not destroy normal cells, but will only target cancer cells to attack molecular target therapy.
Cancer is a group of cancer cells. In order to prevent various cancer cells from evading attack, strengthening acquired immunity and innate immunity is the most ideal method.
Our hospital provides treatment based on a combination of "polyvalent dendritic cell vaccine" and "activated MK cell therapy" based on the patient's condition.
This treatment method uses the immunity of the own immune cells to attack the relationship between cancer, so there are almost no side effects, and the patient can continue to receive cure while maintaining the QOL (quality of life).
.png)
Characteristics of immunotherapy (cell-targeted therapy)
-
It uses the patient's own immunity to fight off cancer cells with almost no side effects.
-
Patients can continue to receive treatment while maintaining their QOL (quality of life).
-
Surgery, chemotherapy, radiation therapy, etc. can be used at the same time.
-
It has a predictable effect on the prevention of recurrence and metastasis.
-
Improvement in quality of life after treatment is predictable
-
Unfortunately, if the patient does not have basic physical strength, such as malnutrition caused by low albumin value, unable to walk or is bedridden, it is difficult to expect therapeutic effects. However, even in this state, improvements in QOL (quality of life) such as increased appetite, increased physical strength, and pain relief can be expected.
Patented technology
Our hospital is always looking for more effective, safe and side-effect-free cancer treatments in which we harness the body's immune system. We have been conducting research steadily since 2000, and some of the developed technologies have gradually achieved research results, including obtaining patents in countries around the world.
In particular, breakthrough patents are a series of technology patents related to the production of dendritic cell vaccines, patented technologies that will significantly reduce the physical burden on patients. The multivalent dendritic cell vaccine provided by our hospital is continuously upgraded using the patented technology platform obtained.
Features of using patented technology "dendritic cell vaccine"
A blood collection method that does not require separation of blood components (Apheresis).
Utilizing monocyte undifferentiated proliferation technology, only 25ml of venous blood is collected each time to produce a single-use dose.
Use overlapping long peptides (cancer antigens)
・HLA (Human Leukocyte Antigen) is not restricted because it is taken up by dendritic cells through endocytosis
・Dendritic cells present antigen to MHC (major histocompatibility complex, Chinese: major histocompatibility complex gene) class I and class II, so CD4+ T cells (T cells with CD4 receptors) are also activated
・CD8+ killer T cells differentiate into aggressive effector T cells.
-
Use 4 to 8 peptides.
・Corresponds to various cancer cells
・If cancer tissue is available, lyse it and use it as an antigen -
Use heat shock protein (HSP70).
・Antigen can be taken up through HSP70 receptor (CD91). -
NK cells are extracted from the collected blood and used as dendritic cell vaccines to proliferate and activate in large quantities.
・Mixed treatment of innate immunity and acquired immunity is possible (corresponding to immune escape).